Stock Financial Ratios and Split History

WVE / WAVE Life Sciences Ltd. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,161.68
Enterprise Value ($M)1,019.18
Book Value ($M)139.81
Book Value / Share4.99
Price / Book8.31
NCAV ($M)124.05
NCAV / Share4.43
Price / NCAV9.07
Income Statement (mra) ($M)
Net Income-102.03
Balance Sheet (mrq) ($M)
Cash & Equivalents0.00
Cash / Share0.00
Quick Ratio7.83
Current Ratio7.83
Share Statistics
Common Stock Shares Outstanding27,829,079
Temporary Equity Shares Outstanding3,901,348
Common Shares Outstanding27,992,244
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.73
Return on Assets (ROA)-0.62
Return on Equity (ROE)-0.76
Identifiers and Descriptors
Central Index Key (CIK)1631574
Industry Groups
SIC 2834 - Pharmaceutical Preparations

Split History

Stock splits are used by WAVE Life Sciences Ltd. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Peers - Pharmaceutical Preparations (2834)

Related News Stories

Your Daily Pharma Scoop: Portola Update, Wave Life Sciences To Collaborate With Takeda, AbbVie Reports Data For Egolix

2018-02-21 seekingalpha
Today we will discuss Portola Pharmaceuticals (PTLA), which came out with some mixed news. PTLA shares were down sharply at the time of writing this note. (227-4)

Ionis Pharmaceuticals Is Poised To Disrupt Biotech

2018-01-24 seekingalpha
Ionis's trials for Alzheimer's, Parkinson's, ALS and Huntington's may produce the first therapies for these previous "undruggable" disorders. (123-1)

Dicerna Pharmaceuticals: Buy The Dip

2017-12-19 seekingalpha
Shares rose by as much as 225% in the past six months before the recent pullback. (19-1)

Your Daily Pharma Scoop: A Look At Sanofi, Ultragenyx Gets FDA Nod, Capricor Tumbles

2017-11-16 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (381-11)

Wave Life Sciences: DMD Program Set To Create Value In 2018

2017-11-07 seekingalpha
It is thought that significantly improved exon 51 skipping efficiency and dystrophin protein restoration observed in preclinical studies could translate into an improved second-generation treatment. (32-1)

CUSIP: Y95308105